Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
NCT03425331 · Dana-Farber Cancer Institute · PHASE2 · terminated · last registry update 2026-07-16 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual, competing studies, and lack of efficacy” | Open Targets' class: negative | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CTLA4 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-23Also stopped (terminated): Hackensack Meridian Health, Nivolumab + Ipilimumab (NCT05715229)
- 2026-06-08Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Favezelimab (NCT03516981)
- 2026-05-26Also stopped (terminated): ImmunityBio, Inc., NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab (NCT03520686)
- 2026-05-15Also stopped (terminated): Iovance Biotherapeutics, Inc., Lifileucel + LN-145 (NCT03645928)
- 2026-05-05Results posted on the registry: Eziafa Oduah, MD, PhD, MPH, Nivolumab + Ipilimumab (NCT05144529)
- 2026-05-05Also stopped (terminated): Eziafa Oduah, MD, PhD, MPH, Nivolumab + Ipilimumab (NCT05144529)
- 2026-04-29Results posted on the registry: Regeneron Pharmaceuticals, REGN2810 + REGN2810/chemo/ipi (NCT03409614)
- 2026-01-08Also stopped (terminated): University Health Network, Toronto, Nivolumab + Ipilimumab (NCT04966676)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision